Litoxetine

Small molecule

IIxaltis SA

Litoxetine is one of 23 small molecule programs targeting Urinary incontinence. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urinary IncontinenceActive, not recruiting

Urinary IncontinencePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Urinary Incontinence

#DrugCompanyPhaseTrials

Vesicare

Astellas

Approved

8 2

Myrbetriq

Astellas

Approved

2 3

Enablex

AbbVie

Approved

—4

Cymbalta

Alnylam Pharmaceuticals

Toviaz

Xylocaine

Alka-Seltzer

Isopto Carpine

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

8 10

Oxytrol

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary incontinence1 trial

DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence

Completed·IIxaltis SA·Phase 1/2·NCT03397771·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Litoxetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Litoxetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Litoxetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ixaltis SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IIxaltis SA

Litoxetine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary incontinence1 trial

References

Drug Info

Quick Facts

Related News